Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa
Key Highlights
- ➤Corvus (CRVS) begins Phase 1b trial of soquelitinib in hidradenitis suppurativa
- ➤Trial plans to enroll up to 25 adults with moderate to severe hidradenitis suppurativa
- ➤Patients receive soquelitinib 200 mg twice daily for 12 weeks
- ➤Soquelitinib advances to fourth clinical indication under development
- ➤Corvus plans Phase 2 asthma trial initiation later this year
Expert Statements
Richard A. Miller, M.D., Co-founder, President and Chief Executive Officer of Corvus Pharmaceuticals
“The initiation of our Phase 1b hidradenitis suppurativa trial provides an important opportunity to expand the potential of soquelitinib to a wider range of diseases.”
Richard A. Miller, M.D., Co-founder, President and Chief Executive Officer of Corvus Pharmaceuticals
“In addition to evaluating safety and efficacy, the trial is designed to evaluate soquelitinib’s ability to modulate Th17-driven disease, complementing the results we have already seen in Th2-driven diseases such as atopic dermatitis.”
Richard A. Miller, M.D., Co-founder, President and Chief Executive Officer of Corvus Pharmaceuticals
“Hidradenitis suppurativa is primarily driven by Th17 cells, which we have shown to be reduced in patients with atopic dermatitis treated with soquelitinib.”
Richard A. Miller, M.D., Co-founder, President and Chief Executive Officer of Corvus Pharmaceuticals
“We look forward to exploring the potential of selective ITK inhibition with soquelitinib to provide an oral and potentially more effective treatment option for hidradenitis suppurativa with a novel mechanism of action.”
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for the treatment of patients with hidradenitis suppurativa.
“The initiation of our Phase 1b hidradenitis suppurativa trial provides an important opportunity to expand the potential of soquelitinib to a wider range of diseases,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “In addition to evaluating safety and efficacy, the trial is designed to evaluate soquelitinib’s ability to modulate Th17-driven disease, complementing the results we have already seen in Th2-driven diseases such as atopic dermatitis. Hidradenitis suppurativa is primarily driven by Th17 cells, which we have shown to be reduced in patients with atopic dermatitis treated with soquelitinib. We look forward to exploring the potential of selective ITK inhibition with soquelitinib to provide an oral and potentially more effective treatment option for hidradenitis suppurativa with a novel mechanism of action.”
Get started
Create a free account to read the full story.